Cargando…

LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD

Airway inflammation in chronic obstructive pulmonary disease (COPD) is partially insensitive/resistant to inhaled corticosteroids (ICS). ICS plus bronchodilator therapy has been discussed for COPD phenotypes with frequent exacerbations and participation of corticosteroid-sensitive type 2/eosinophili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knobloch, Jürgen, Jungck, David, Kronsbein, Juliane, Stoelben, Erich, Ito, Kazuhiro, Koch, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947523/ https://www.ncbi.nlm.nih.gov/pubmed/31766770 http://dx.doi.org/10.3390/jcm8122058

Ejemplares similares

Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD
por: Jamal Jameel, Kaschin, et al.
Publicado: (2021)

Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD
por: Khorasani, Nadia, et al.
Publicado: (2015)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Olfactory Receptors Modulate Physiological Processes in Human Airway Smooth Muscle Cells
por: Kalbe, Benjamin, et al.
Publicado: (2016)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD
por: Lewis, Brandon W., et al.
Publicado: (2021)

Corticosteroid insensitivity in severe asthma: impaired nuclear translocation of glucocorticoid receptor in airway smooth muscle cells
por: Bhavsar, Pankaj, et al.
Publicado: (2013)

Th1 cytokines synergize to change gene expression and promote corticosteroid insensitivity in pediatric airway smooth muscle
por: Jackson, Devine, et al.
Publicado: (2022)

Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi
por: Khalaf, Rana M., et al.
Publicado: (2017)

The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD
por: Russell, Kirsty E., et al.
Publicado: (2016)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Suhuang Antitussive Capsule Ameliorates Corticosteroid Insensitivity in Cough Variant Asthma Guinea Pigs by Inhibiting p38 MAPK Signal Pathway
por: Lyu, Tianyi, et al.
Publicado: (2022)

Repeated lipopolysaccharide exposure causes corticosteroid insensitive airway inflammation via activation of phosphoinositide-3-kinase δ pathway
por: Ueda, Keitaro, et al.
Publicado: (2016)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Defects of Protein Phosphatase 2A Causes Corticosteroid Insensitivity in Severe Asthma
por: Kobayashi, Yoshiki, et al.
Publicado: (2011)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

Glucocorticoid Insensitivity in Asthma: The Unique Role for Airway Smooth Muscle Cells
por: Ramos-Ramírez, Patricia, et al.
Publicado: (2022)

Is the Combination of ICS and LABA, a Therapeutic Option for COPD, Fading Away?
por: Oh, Yeon-Mok
Publicado: (2017)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV(1) in COPD patients
por: Huang, Cuiping, et al.
Publicado: (2013)

Shot Down Inflamed: Airway Smooth Muscle Bronchodilator Insensitivity in Cystic Fibrosis
por: Pascoe, Christopher D., et al.
Publicado: (2019)

Airway Smooth Muscle Cell Mitochondria Damage and Mitophagy in COPD via ERK1/2 MAPK
por: Fang, Lei, et al.
Publicado: (2022)

Corticosteroid insensitivity persists in the absence of STAT1 signaling in severe allergic airway inflammation
por: Lewis, Brandon W., et al.
Publicado: (2021)

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
por: Spina, Domenico
Publicado: (2015)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2018)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

Chronic Allergen Challenge Induces Corticosteroid Insensitivity With Persistent Airway Remodeling and Type 2 Inflammation
por: Lewis, Brandon W., et al.
Publicado: (2022)

Predictors of ICS/LABA prescribing in COPD patients: a study from general practice
por: Drivenes, Elin, et al.
Publicado: (2014)

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts
por: Dhar, Raja, et al.
Publicado: (2022)

Airway Smooth Muscle Regulated by Oxidative Stress in COPD
por: Kume, Hiroaki, et al.
Publicado: (2023)

Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
por: Tariq, Syed Mohammad, et al.
Publicado: (2017)

Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
por: Gong, Yiwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_meffh5ugdhp0gnoclmjr3h3du8